TTN and neoplasm: Treatment of shRNA-TTN-AS1 significantly inhibited cell proliferation in situ (Fig. 4d, e) and reduced tumor vasculature, while antagomiR-320a neutralized the effects of shRNA-TTN-AS1 (Fig. 4d, f).